OTC Switch “Blueprint” Could Help Regulatory Navigation – Researchers
This article was originally published in The Tan Sheet
Executive Summary
Rx-to-OTC switch questions that FDA asked advisory committees over the past 10 years can help guide future sponsors to success, says the lead researcher in an analysis of the agency’s switch actions.